Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 pre-specified symptom endpoints.

A grassroots organization that formed with the goal of recalibrating cancer care around patient needs issued guidance ...

representing a significant clinical advantage. The efficacy appears higher than previously reported in the US Phase 3 trial 3,4 and adds to a growing body of evidence. Recent real-world data was ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its ...

"On behalf of Renibus and the clinical study team ... enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal trial and announced completion of enrollment in April 2025.

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 ... or completed clinical trials exploring the ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be ...

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for ...